Online inquiry

IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12772MR)

This product GTTS-WQ12772MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH1 gene. The antibody can be applied in Lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_017617.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4851
UniProt ID P46531
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12772MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6467MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ4815MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ14349MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ14002MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ9822MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ6832MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ6428MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ14470MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW